Akari Therapeutics (AKTX) Proxy filing summary

Executive summary

• A general meeting is scheduled for October 28, 2026, to vote on increasing shares available under the 2023 Equity Incentive Plan by 144 billion ordinary shares, raising the total to 163.8 billion shares (2,047,575 ADSs), plus additional shares from forfeited or expired awards under the 2014 plan.

• The Board unanimously recommends voting in favor, citing the need for continued equity-based incentives for employees, consultants, and directors.

• Proxy materials were distributed to both ordinary shareholders and ADS holders, with specific instructions and deadlines for voting.

Voting matters and shareholder proposals

• The sole resolution is to approve the increase in shares available under the 2023 Equity Incentive Plan.

• Shareholders and ADS holders have detailed instructions for proxy voting, with deadlines and procedures for revoking or changing votes.

• No other business will be conducted at the meeting.

• Shareholders can submit proposals for the 2027 AGM, with deadlines and requirements outlined.

Board of directors and corporate governance

• The Board and compensation committee oversee the administration of the equity plan, including eligibility, award types, and plan amendments.

• The Board has determined the share increase is in the best interests of shareholders and the company.

• Information on beneficial ownership of shares by directors, officers, and major shareholders is disclosed.